{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:02:58Z","timestamp":1740139378451,"version":"3.37.3"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:00:00Z","timestamp":1648425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011000","name":"Mission Interminist\u00e9rielle de Lutte Contre les Drogues et les Conduites Addictives","doi-asserted-by":"publisher","award":["PREVDROG 2011"],"award-info":[{"award-number":["PREVDROG 2011"]}],"id":[{"id":"10.13039\/501100011000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009411","name":"Universit\u00e9 Paris-Est Cr\u00e9teil Val-de-Marne","doi-asserted-by":"crossref","award":["PREVDROG 2011"],"award-info":[{"award-number":["PREVDROG 2011"]}],"id":[{"id":"10.13039\/501100009411","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The resurgence of heroin use and the misuse of pharmaceutical opioids are some of the reasons for a worldwide increase in opioid dependence. Opioid Medication Therapies (OMT) have amply demonstrated their efficacy. From a medical point of view, the main objectives of OMT concern medical and social outcomes, centred on risk reduction and the cessation of opioid use. But patient points of view can differ and few studies have explored opioid-dependent patient viewpoints on their OMT. This variable seems important to consider in a patient-centred approach. The aim of our study was to explore points of view of people who use drugs (PWUD) treated with OMT, in a large multicentre sample.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A cross-sectional multicentre study explored the points of view of PWUD with Opioid Use Disorder following OMT. Data regarding the patients\u2019 points of view were collected using a self-administered questionnaire developed by the scientific committee of the study. A descriptive analysis and an exploratory factor analysis were performed to explore the structure of items exploring patient viewpoints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>263 opioid dependent PWUD were included, a majority were men consuming heroin prior to being prescribed OMT. 68% were on methadone, 32% were on buprenorphine. Most PWUD identified a positive impact on their lives, with 92.8% agreeing or strongly agreeing that OMT had changed a lot of things in their lives. The exploratory factor analysis identified three factors: (F1) items related to points of views concerning the objectives and efficacy of OMT; (F2) items related to the legitimacy of OMT as a treatment compared to a drug, (F3) items related to experiences and relationships with OMT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patient viewpoints on efficacy were correlated with the pharmacological benefits of OMT and with the associated psychosocial measures. The implications of OMT in relationships, such as the feeling of being judged, concerned a majority. Points of view were ambivalent concerning the role of OMT as a treatment or as a drug. Involving patient points of view in therapeutic strategies decisions could help enhance positive views among PWUD on OMT and help PWUD towards their recovery.<\/jats:p>\n                <jats:p><jats:italic>Trial registration:<\/jats:italic> OPAL study was registered: (NCT01847729).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-022-00608-6","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T22:03:02Z","timestamp":1648504982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["How do people who use drugs receiving Opioid Medication Therapy perceive their treatment ? A multicentre study"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1568-9480","authenticated-orcid":false,"given":"Morgane","family":"Guillou Landreat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Dany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaelle","family":"Challet Bouju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard-Jules","family":"Laforgue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cholet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Leboucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Benoit","family":"Hardouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the OPAL Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Bodenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Grall-Bronnec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgane","family":"Guillou-Landreat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Le Geay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Martineau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Levassor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Bolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Guillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Guillery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corine","family":"Dano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Victorri Vigneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Grall Bronnec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,28]]},"reference":[{"issue":"5","key":"608_CR1","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1213\/ANE.0000000000002403","volume":"125","author":"CD Soelberg","year":"2017","unstructured":"Soelberg CD, Brown RE Jr, Du Vivier D, Meyer JE, Ramachandran BK. The US opioid crisis: current federal and state legal issues. Anesth Analg. 2017;125(5):1675\u201381.","journal-title":"Anesth Analg"},{"key":"608_CR2","unstructured":"Labors UNOoDa. World drug report 2018 (set of 5 booklets). 2018. Contract No. https:\/\/www.unodc.org\/wdr2018 [Google Scholar]."},{"key":"608_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. Int J Drug Policy. 2017;46:107\u201311.","journal-title":"Int J Drug Policy"},{"key":"608_CR4","unstructured":"The global burden of disease attributable to alcohol and drug use in 195 countries and territories -. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5(12):987\u20131012."},{"issue":"3","key":"608_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3122\/jabfm.2014.03.130290","volume":"27","author":"LJ Paulozzi","year":"2014","unstructured":"Paulozzi LJ, Zhang K, Jones CM, Mack KA. Risk of adverse health outcomes with increasing duration and regularity of opioid therapy. J Am Board Fam Med. 2014;27(3):329\u201338.","journal-title":"J Am Board Fam Med"},{"issue":"10","key":"608_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076931","volume":"8","author":"L Zhang","year":"2013","unstructured":"Zhang L, Zhang D, Chen W, Zou X, Li L. High prevalence of HIV, HCV and tuberculosis and associated risk behaviours among new entrants of methadone maintenance treatment clinics in Guangdong Province, China. PLoS ONE. 2013;8(10): e76931.","journal-title":"PLoS ONE"},{"issue":"1","key":"608_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2165\/00003495-199753010-00004","volume":"53","author":"ME Klepser","year":"1997","unstructured":"Klepser ME, Klepser TB. Drug treatment of HIV-related opportunistic infections. Drugs. 1997;53(1):40\u201373.","journal-title":"Drugs"},{"issue":"Suppl 1","key":"608_CR8","doi-asserted-by":"publisher","first-page":"S77","DOI":"10.1086\/313842","volume":"30","author":"MS Sulkowski","year":"2000","unstructured":"Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis. 2000;30(Suppl 1):S77-84.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"608_CR9","first-page":"417","volume":"18","author":"D Basu","year":"2009","unstructured":"Basu D, Banerjee A, Harish T, Mattoo S. Disproportionately high rate of epileptic seizure in patients abusing dextropropoxyphene. Am J Addict Am Acad Psychiatr Alcohol Addict. 2009;18(5):417\u201321.","journal-title":"Am J Addict Am Acad Psychiatr Alcohol Addict"},{"issue":"5 pt 1","key":"608_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/BF03011931","volume":"44","author":"P Manninen","year":"1997","unstructured":"Manninen P. Opioids and seizures. Can J Anaesth. 1997;44(5 pt 1):463\u20136.","journal-title":"Can J Anaesth"},{"issue":"2","key":"608_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/1556365050014418","volume":"44","author":"V Jovanovic-Cupic","year":"2006","unstructured":"Jovanovic-Cupic V, Martinovic Z, Nesic N. Seizures associated with intoxication and abuse of tramadol. Clin Toxicol. 2006;44(2):143\u20136.","journal-title":"Clin Toxicol"},{"issue":"4","key":"608_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1440-1819.2009.01980.x","volume":"63","author":"S Mattoo","year":"2009","unstructured":"Mattoo S, Singh S, Bhardwaj R, Kumar S, Basu D, Kulhara P. Prevalence and correlates of epileptic seizure in substance-abusing subjects. Psychiatry Clin Neurosci. 2009;63(4):580\u20132.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"8","key":"608_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/070674371105600808","volume":"56","author":"E Amari","year":"2011","unstructured":"Amari E, Rehm J, Goldner E, Fischer B. Nonmedical prescription opioid use and mental health and pain comorbidities: a narrative review. Can J Psychiatry. 2011;56(8):495\u2013502.","journal-title":"Can J Psychiatry"},{"issue":"11","key":"608_CR14","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jpain.2012.09.003","volume":"13","author":"A Kobus","year":"2012","unstructured":"Kobus A, Smith D, Morasco B, et al. Correlates of higher-dose opioid medication use for low back pain in primary care. J Pain. 2012;13(11):1131\u20138.","journal-title":"J Pain"},{"issue":"1","key":"608_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12888-019-2098-3","volume":"19","author":"M Fridell","year":"2019","unstructured":"Fridell M, B\u00e4ckstr\u00f6m M, Hesse M, Krantz P, Perrin S, Nyhl\u00e9n A. Prediction of psychiatric comorbidity on premature death in a cohort of patients with substance use disorders: a 42-year follow-up. BMC Psychiatry. 2019;19(1):150.","journal-title":"BMC Psychiatry"},{"issue":"12 Pt 1","key":"608_CR16","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.lpm.2012.07.030","volume":"41","author":"P Courty","year":"2012","unstructured":"Courty P, Authier N. Pain in patients with opiates dependence. Presse Med. 2012;41(12 Pt 1):1221\u20135.","journal-title":"Presse Med"},{"issue":"suppl. 1","key":"608_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/pme.12914","volume":"16","author":"P Yi","year":"2015","unstructured":"Yi P, Pryzbylkowski P. Opioid Induced Hyperalgesia. Pain Med. 2015;16(suppl. 1):32\u20136.","journal-title":"Pain Med"},{"issue":"6","key":"608_CR18","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1016\/j.bja.2018.09.019","volume":"122","author":"C Higgins","year":"2019","unstructured":"Higgins C, Smith B, Matthews K. Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. Br J Anaesth. 2019;122(6):e114\u201326.","journal-title":"Br J Anaesth"},{"key":"608_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fpsyt.2018.00335","volume":"9","author":"J Delorme","year":"2018","unstructured":"Delorme J, Chenaf C, Bertin C, Riquelme M, Eschalier A, Ardid D, et al. Chronic pain opioid-maintained patients receive less analgesic opioid prescriptions. Front Psychiatry. 2018;9:335.","journal-title":"Front Psychiatry"},{"issue":"6","key":"608_CR20","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/QAD.0000000000001039","volume":"30","author":"DC Des Jarlais","year":"2016","unstructured":"Des Jarlais DC, Kerr T, Carrieri P, Feelemyer J, Arasteh K. HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. AIDS. 2016;30(6):815\u201326.","journal-title":"AIDS"},{"key":"608_CR21","first-page":"39","volume":"2013","author":"M Jauffret-Roustide","year":"2011","unstructured":"Jauffret-Roustide M, Pillonel J, Weill-Barillet L, L\u00e9on L, Le Strat Y, Brunet S, et al. Estimation de la s\u00e9ropr\u00e9valence du VIH et de l\u2019h\u00e9patite C chez les usagers de drogues en France- Premiers r\u00e9sultats de l\u2019enqu\u00eate ANRS-Coquelicot. BEH. 2011;2013:39\u201340.","journal-title":"BEH"},{"issue":"2","key":"608_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000468518","volume":"23","author":"M Soyka","year":"2017","unstructured":"Soyka M, Strehle J, Rehm J, Buhringer G, Wittchen HU. Six-year outcome of opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative sample. Eur Addict Res. 2017;23(2):97\u2013105.","journal-title":"Eur Addict Res"},{"key":"608_CR23","unstructured":"World Health Organization. World Health Orgnaization Organization: the world health report. Geneva 2004. Contract No. https:\/\/www.who.int\/whr\/2004\/en\/ [Google Scholar]."},{"key":"608_CR24","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). American Psychiatric Association ed. Washington, DC. 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"18","key":"608_CR25","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1080\/14656566.2017.1409722","volume":"18","author":"M Dematteis","year":"2017","unstructured":"Dematteis M, Auriacombe M, D\u2019Agnone O, Somaini L, Szerman N, Littlewood R, et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother. 2017;18(18):1987\u201399.","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"608_CR26","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2017.0001","volume":"317","author":"S Nielsen","year":"2017","unstructured":"Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescription opioids. JAMA. 2017;317(9):967\u20138.","journal-title":"JAMA"},{"key":"608_CR27","first-page":"CD011117","volume":"5","author":"S Nielsen","year":"2016","unstructured":"Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;5:CD011117.","journal-title":"Cochrane Database Syst Rev"},{"key":"608_CR28","unstructured":"OFDT. Barom\u00e8tre Sant\u00e9 2017 Paris 2018. https:\/\/www.ofdt.fr\/statistiques-et-infographie\/sources-statistiques\/barometre-sante-alcool\/."},{"issue":"6","key":"608_CR29","first-page":"367","volume":"171","author":"M Guillou Landreat","year":"2013","unstructured":"Guillou Landreat M, Victorri-Vigneau C, Grall-Bronnec M, Sebille-Rivain V, Venisse JL, Jolliet P. Impact des politiques de sant\u00e9 publique sur les consultations en addictologie \u00e0 partir d\u2019un suivi longitudinal de 1998 \u00e0 2007. Ann Med Psy. 2013;171(6):367\u201371.","journal-title":"Ann Med Psy"},{"issue":"10","key":"608_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137708","volume":"10","author":"M Guillou Landreat","year":"2015","unstructured":"Guillou Landreat M, Rozaire C, Guillet JY, Victorri Vigneau C, Le Reste JY, Grall Bronnec M. French Experience with Buprenorphine\u202f: Do Physicians Follow the Guidelines? PLoS ONE. 2015;10(10): e0137708.","journal-title":"PLoS ONE"},{"issue":"5","key":"608_CR31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","volume":"9","author":"M Fatseas","year":"2007","unstructured":"Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007;9(5):358\u201364.","journal-title":"Curr Psychiatry Rep"},{"key":"608_CR32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000506630","volume":"26","author":"J Dupouy","year":"2020","unstructured":"Dupouy J, Maumus-Robert S, Mansiaux Y, Pariente A, Lapeyre-Mestre M. Primary care of opioid use disorder: the end of \u201cthe French model\u201d? Eur Addict Res. 2020;26:346\u201354.","journal-title":"Eur Addict Res"},{"key":"608_CR33","doi-asserted-by":"crossref","unstructured":"ANAES, sant\u00e9 Andaed\u00e9e. Strat\u00e9gies th\u00e9rapeutiques pour les personnes d\u00e9pendantes des opiac\u00e9s: place des traitements de substitution. Presse M\u00e9dicale. 2004;33(18):41\u20137.","DOI":"10.1016\/S0755-4982(04)72381-7"},{"key":"608_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1477-7517-8-23","volume":"8","author":"J Trujols","year":"2011","unstructured":"Trujols J, Sinol N, Iraurgi I, Batlle F, Guardia J, Perez de Los Cobos J. Patient and clinician\u2019s ratings of improvement in methadone-maintained patients: differing perspectives? Harm Reduct J. 2011;8:23.","journal-title":"Harm Reduct J"},{"issue":"2","key":"608_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1080\/02791072.2014.904061","volume":"46","author":"M Guillou Landreat","year":"2014","unstructured":"Guillou Landreat M, Sebille-Rivain V, Victorri Vigneau C, Foucher Y, Venisse JL, Jolliet P. Buprenorphine prescription compliance: an original observational and longitudinal study. J Psychoactive Drugs. 2014;46(2):162\u20137.","journal-title":"J Psychoactive Drugs"},{"key":"608_CR36","doi-asserted-by":"crossref","unstructured":"Guillou Landreat M. Repr\u00e9sentation des traitements de substitution aux opiac\u00e9s et de leur arr\u00eat. Regards crois\u00e9s patients-m\u00e9decins. 2013:23\u201344.","DOI":"10.3917\/psyt.192.0023"},{"key":"608_CR37","unstructured":"Drugs ACotMo. How can opioid substitution therapy be optimised to maximise recovery outcomes for service users? 2019. Contract No. https:\/\/www.gov.uk\/government\/publications\/how-can-opioid-substitution-therapy-be-optimised-to-maximise-recovery-outcomes-for-service-users. ."},{"key":"608_CR38","unstructured":"Comer S, Cunningham C, Fishman M, Gordon A, Kampman K, Langle ben D, et al. American Society of Addiction Medicine (ASAM). National practice guideline for the use of medications in the treatment of addiction involving opioid use. 2015."},{"issue":"1","key":"608_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","volume":"106","author":"L Degenhardt","year":"2011","unstructured":"Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011;106(1):32\u201351.","journal-title":"Addiction"},{"issue":"5","key":"608_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O'Connor","year":"2020","unstructured":"O\u2019Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. PLoS ONE. 2020;15(5): e0232086.","journal-title":"PLoS ONE"},{"key":"608_CR41","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"key":"608_CR42","unstructured":"Guichard A, Lert F, Maguet O. \u00abDu point de vue des usagers quels sont les effets, les B\u00e9n\u00e9fices et les difficult\u00e9s suscit\u00e9s par les TSO\u00a0? Alccologie et Addictologie. 2004;26(4)."},{"issue":"2","key":"608_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0740-5472(03)00156-9","volume":"25","author":"AT McLellan","year":"2003","unstructured":"McLellan AT, Carise D, Kleber HD. Can the national addiction treatment infrastructure support the public\u2019s demand for quality care? J Subst Abuse Treat. 2003;25(2):117\u201321.","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"608_CR44","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/09595230801935706","volume":"27","author":"A Madden","year":"2008","unstructured":"Madden A, Lea T, Bath N, Winstock AR. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug Alcohol Rev. 2008;27(6):671\u20138.","journal-title":"Drug Alcohol Rev"},{"issue":"3","key":"608_CR45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/PRA.0000000000000231","volume":"23","author":"S Hassamal","year":"2017","unstructured":"Hassamal S, Goldenberg M, Ishak W, Haglund M, Miotto K, Danovitch I. Overcoming barriers to initiating medication-assisted treatment for heroin use disorder in a general medical hospital: a case report and narrative literature review. J Psychiatr Pract. 2017;23(3):221\u20139.","journal-title":"J Psychiatr Pract"},{"key":"608_CR46","first-page":"3019","volume":"15","author":"JR DeFlavio","year":"2015","unstructured":"DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA Jr. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health. 2015;15:3019.","journal-title":"Rural Remote Health"},{"key":"608_CR47","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3389\/fpsyt.2019.00726","volume":"10","author":"M Grall-Bronnec","year":"2019","unstructured":"Grall-Bronnec M, Laforgue EJ, Challet-Bouju G, Cholet J, Hardouin JB, Leboucher J, et al. Prevalence of coaddictions and rate of successful treatment among a french sample of opioid-dependent patients with long-term opioid substitution therapy: the OPAL study. Front Psychiatry. 2019;10:726.","journal-title":"Front Psychiatry"},{"issue":"7","key":"608_CR48","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1111\/bcp.13936","volume":"85","author":"C Victorri-Vigneau","year":"2019","unstructured":"Victorri-Vigneau C, Verstuyft C, Bouquie R, Laforgue EJ, Hardouin JB, Leboucher J, et al. Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study. Br J Clin Pharmacol. 2019;85(7):1538\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"608_CR49","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC. 1994."},{"issue":"11","key":"608_CR50","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.3390\/ijerph18115749","volume":"18","author":"M Guillou-Landreat","year":"2021","unstructured":"Guillou-Landreat M, Levassor P, Guerlais M, Sebille V, Victorri-Vigneau C. Prospective study on factors associated with referral of patients with opioid maintenance therapy from specialized addictive disorders centers to primary care. Int J Environ Res Public Health. 2021;18(11):5749.","journal-title":"Int J Environ Res Public Health"},{"issue":"9","key":"608_CR51","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1360-0443.1991.tb01879.x","volume":"86","author":"TF Heatherton","year":"1991","unstructured":"Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict. 1991;86(9):1119\u201327.","journal-title":"Br J Addict"},{"issue":"4 Pt 1","key":"608_CR52","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.lpm.2007.01.005","volume":"36","author":"L Karila","year":"2007","unstructured":"Karila L, Legleye S, Beck F, Corruble E, Falissard B, Reynaud M. Validation of a questionnaire to screen for harmful use of alcohol and cannabis in the general population: CRAFFT-ADOSPA. Presse Med. 2007;36(4 Pt 1):582\u201390.","journal-title":"Presse Med"},{"issue":"1","key":"608_CR53","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2466\/pr0.1997.80.1.83","volume":"80","author":"EE Johnson","year":"1997","unstructured":"Johnson EE, Hamer R, Nora RM, Tan B, Eisenstein N, Engelhart C. The Lie\/Bet Questionnaire for screening pathological gamblers. Psychol Rep. 1997;80(1):83\u20138.","journal-title":"Psychol Rep"},{"key":"608_CR54","unstructured":"Langlois E, Milhet M. Les traitements de subsitution aux opiac\u00e9s vus par les patients Tendances 2012;83 (OFDT ):4p. ."},{"key":"608_CR55","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.drugalcdep.2018.02.018","volume":"187","author":"AE Muller","year":"2018","unstructured":"Muller AE, Bjornestad R, Clausen T. Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications. Drug Alcohol Depend. 2018;187:22\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"608_CR56","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jsat.2016.07.006","volume":"69","author":"J Teoh Bing Fei","year":"2016","unstructured":"Teoh Bing Fei J, Yee A, Habil MH, Danaee M. Effectiveness of methadone maintenance therapy and improvement in quality of life following a decade of implementation. J Subst Abuse Treat. 2016;69:50\u20136.","journal-title":"J Subst Abuse Treat"},{"issue":"10","key":"608_CR57","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.ijnurstu.2011.03.009","volume":"48","author":"J De Maeyer","year":"2011","unstructured":"De Maeyer J, Vanderplasschen W, Camfield L, Vanheule S, Sabbe B, Broekaert E. A good quality of life under the influence of methadone: a qualitative study among opiate-dependent individuals. Int J Nurs Stud. 2011;48(10):1244\u201357.","journal-title":"Int J Nurs Stud"},{"issue":"4","key":"608_CR58","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","volume":"93","author":"W Ling","year":"1998","unstructured":"Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93(4):475\u201386.","journal-title":"Addiction"},{"issue":"3","key":"608_CR59","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.drugalcdep.2003.11.002","volume":"73","author":"L Amato","year":"2004","unstructured":"Amato L, Davoli M, Ferri M, Gowing L, Perucci CA. Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend. 2004;73(3):219\u201326.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"608_CR60","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1046\/j.1360-0443.2001.9656834.x","volume":"96","author":"PG Barnett","year":"2001","unstructured":"Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001;96(5):683\u201390.","journal-title":"Addiction"},{"issue":"2","key":"608_CR61","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","volume":"10","author":"K Dugosh","year":"2016","unstructured":"Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):93\u2013103.","journal-title":"J Addict Med"},{"issue":"2","key":"608_CR62","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/bcp.12051","volume":"77","author":"J Bell","year":"2014","unstructured":"Bell J. Pharmacological maintenance treatments of opiate addiction. Br J Clin Pharmacol. 2014;77(2):253\u201363.","journal-title":"Br J Clin Pharmacol"},{"key":"608_CR63","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1192\/bjp.176.3.285","volume":"176","author":"J Marsden","year":"2000","unstructured":"Marsden J, Gossop M, Stewart D, Rolfe A, Farrell M. Psychiatric symptoms among clients seeking treatment for drug dependence. Intake data from the National Treatment Outcome Research Study. Br J Psychiatry. 2000;176:285\u20139.","journal-title":"Br J Psychiatry"},{"key":"608_CR64","first-page":"1","volume":"1","author":"VP Dole","year":"1973","unstructured":"Dole VP, Nyswander M. Rehabilitation of patients on methadone programs. Proc Natl Conf Methadone Treat. 1973;1:1\u20137.","journal-title":"Proc Natl Conf Methadone Treat"},{"key":"608_CR65","unstructured":"Costes J-M, Le N\u00e9zet O, Spilka S, laffiteau C. Dix ans d'\u00e9volution des perceptions et des opinions des fran\u00e7ais sur les drogues (1999\u20132008). Tendance 2010;71(Aout 2010 )."},{"issue":"5","key":"608_CR66","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1370\/afm.2261","volume":"16","author":"ST Tong","year":"2018","unstructured":"Tong ST, Hochheimer CJ, Peterson LE, Krist AH. Buprenorphine provision by early career family physicians. Ann Fam Med. 2018;16(5):443\u20136.","journal-title":"Ann Fam Med"},{"issue":"11\u201312","key":"608_CR67","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3109\/10826088509047261","volume":"20","author":"DE Hunt","year":"1985","unstructured":"Hunt DE, Lipton DS, Goldsmith DS, Strug DL, Spunt B. \u201cIt takes your heart\u201d: the image of methadone maintenance in the addict world and its effect on recruitment into treatment. Int J Addict. 1985;20(11\u201312):1751\u201371.","journal-title":"Int J Addict"},{"issue":"3","key":"608_CR68","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0740-5472(03)00124-7","volume":"25","author":"AT McLellan","year":"2003","unstructured":"McLellan AT. Crime and punishment and treatment: latest findings in the treatment of drug-related offenders. J Subst Abuse Treat. 2003;25(3):187\u20138.","journal-title":"J Subst Abuse Treat"},{"key":"608_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.113986","volume":"279","author":"G Bardwell","year":"2021","unstructured":"Bardwell G, Small W, Lavalley J, McNeil R, Kerr T. \u201cPeople need them or else they\u2019re going to take fentanyl and die\u201d: a qualitative study examining the \u2018problem\u2019 of prescription opioid diversion during an overdose epidemic. Soc Sci Med. 2021;279: 113986.","journal-title":"Soc Sci Med"},{"issue":"5","key":"608_CR70","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","volume":"8","author":"MR Lofwall","year":"2014","unstructured":"Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med. 2014;8(5):315\u201326.","journal-title":"J Addict Med"},{"issue":"5","key":"608_CR71","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.annemergmed.2018.11.032","volume":"73","author":"AA Herring","year":"2019","unstructured":"Herring AA, Perrone J, Nelson LS. Managing opioid withdrawal in the emergency department with buprenorphine. Ann Emerg Med. 2019;73(5):481\u20137.","journal-title":"Ann Emerg Med"},{"key":"608_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2017.04.021","volume":"178","author":"CJ Banta-Green","year":"2017","unstructured":"Banta-Green CJ, Coffin PO, Schoeppe JA, Merrill JO, Whiteside LK, Ebersol AK. Heroin and pharmaceutical opioid overdose events: emergency medical response characteristics. Drug Alcohol Depend. 2017;178:1\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20133","key":"608_CR73","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.drugalcdep.2007.11.003","volume":"94","author":"T Clausen","year":"2008","unstructured":"Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1\u20133):151\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"608_CR74","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1360-0443.2005.01012.x","volume":"100","author":"AT McLellan","year":"2005","unstructured":"McLellan AT, McKay JR, Forman R, Cacciola J, Kemp J. Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addiction. 2005;100(4):447\u201358.","journal-title":"Addiction"},{"key":"608_CR75","unstructured":"Sindicich N, Zador D, Larney S, Dolan K. Patients motivations, perceptions and experiences of opioid substitution therapy in prison Sydney National Drug and Alcohol Research Centre University of New South Wales 2016."},{"key":"608_CR76","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.drugpo.2012.10.003","volume":"24","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T. Methadone diversion as a protective strategy: The harm reduction potential of \u201cgenerous constraints.\u201d Int J Drug Policy. 2013;24:e43\u201350.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"608_CR77","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0009-9236(99)90090-5","volume":"65","author":"KR Dyer","year":"1999","unstructured":"Dyer KR, Foster DJ, White JM, Somogyi AA, Menelaou A, Bochner F. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clin Pharmacol Ther. 1999;65(6):685\u201394.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"608_CR78","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.pharma.2009.06.001","volume":"67","author":"P Chappard","year":"2009","unstructured":"Chappard P. Opiate substitution: the users\u2019 point of view. Ann Pharm Fr. 2009;67(5):365\u20138.","journal-title":"Ann Pharm Fr"},{"issue":"2","key":"608_CR79","first-page":"253","volume":"267","author":"T D'Aunno","year":"1992","unstructured":"D\u2019Aunno T, Vaughn TE. Variations in methadone treatment practices. Results from a national study JAMA. 1992;267(2):253\u20138.","journal-title":"Results from a national study JAMA"},{"issue":"3","key":"608_CR80","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/ijerph16030447","volume":"16","author":"AGI Maremmani","year":"2019","unstructured":"Maremmani AGI, Pacini M, Maremmani I. What we have learned from the Methadone Maintenance Treatment of Dual Disorder Heroin Use Disorder patients. Int J Environ Res Public Health. 2019;16(3):447.","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"608_CR81","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1360-0443.2007.01762.x","volume":"102","author":"J Strang","year":"2007","unstructured":"Strang J, Manning V, Mayet S, Ridge G, Best D, Sheridan J. Does prescribing for opiate addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995\u20132005. Addiction. 2007;102(5):761\u201370.","journal-title":"Addiction"},{"issue":"9697","key":"608_CR82","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/S0140-6736(09)61420-3","volume":"374","author":"J Marsden","year":"2009","unstructured":"Marsden J, Eastwood B, Bradbury C, Dale-Perera A, Farrell M, Hammond P, et al. Effectiveness of community treatments for heroin and crack cocaine addiction in England: a prospective, in-treatment cohort study. Lancet. 2009;374(9697):1262\u201370.","journal-title":"Lancet"},{"issue":"2","key":"608_CR83","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/146642406908900214","volume":"89","author":"PH Connell","year":"1969","unstructured":"Connell PH. Drug taking in Great Britain A growing problem. R Soc Health J. 1969;89(2):92\u20136.","journal-title":"R Soc Health J"},{"key":"608_CR84","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.drugalcdep.2017.05.002","volume":"177","author":"Q Guan","year":"2017","unstructured":"Guan Q, Khuu W, Spithoff S, Kiran T, Kahan M, Tadrous M, et al. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014. Drug Alcohol Depend. 2017;177:315\u201321.","journal-title":"Drug Alcohol Depend"},{"key":"608_CR85","unstructured":"OFDT. Drogues, chiffres cl\u00e9s , 8 th ed. . Paris 2019."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00608-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-022-00608-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00608-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T12:12:16Z","timestamp":1666354336000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-022-00608-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,28]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1186\/s12954-022-00608-6","relation":{},"ISSN":["1477-7517"],"issn-type":[{"type":"electronic","value":"1477-7517"}],"subject":[],"published":{"date-parts":[[2022,3,28]]},"assertion":[{"value":"18 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by Groupe Nantais d\u2019\u00c9thique dans le Domaine de la Sant\u00e9 (GNEDS), the Advisory Committee on the Processing of Health Research Information (CCTIRS) and the Data Protection Commission (CNIL). The patients\/participants provided written informed consent to participate in this study. The OPAL study was registered: (NCT01847729).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}